Clinical Guides
Sarcoidosis
A clinically focused, India-adapted guide to suspected sarcoidosis that prioritises exclusion of tuberculosis and other granulomatous disease, organ-risk assessment, multidisciplinary diagnosis and safe follow-up.
MedNext Academy | 12 min read
Sarcoidosis
A clinically focused, India-adapted guide to suspected sarcoidosis that prioritises exclusion of tuberculosis and other granulomatous disease, organ-risk assessment, multidisciplinary diagnosis and safe follow-up.
Summary
Sarcoidosis is a multisystem inflammatory disorder characterised pathologically by non-necrotising granulomatous inflammation in a compatible clinical setting. It most commonly affects intrathoracic lymph nodes and lungs, but skin, eyes, liver, spleen, peripheral nerves, heart, kidneys, joints and nervous system can be involved. A granuloma is a tissue reaction, not a diagnosis: tuberculosis, fungal infection, malignancy, hypersensitivity pneumonitis, beryllium or silica exposure, drug reactions and immune disorders can produce overlapping pictures. In India, assuming sarcoidosis from bilateral hilar adenopathy or a non-necrotising biopsy without actively considering tuberculosis can cause serious harm.
Diagnosis rests on three linked elements: a compatible syndrome, histology showing non-necrotising granulomas when tissue is needed, and credible exclusion of alternative causes. Some classic presentations can be managed with close follow-up without biopsy, but that is a specialist decision. Treatment is not automatic. Many people improve without systemic immunosuppression, whereas progressive pulmonary disease or involvement that threatens vision, cardiac function, neurological function or another organ needs timely specialist treatment. This educational draft is reviewed and has been reviewed by the MedNext Clinical Team; it is not a substitute for local TB, ophthalmology, cardiology, pathology or respiratory pathways.
How Common Is It?
The apparent frequency of sarcoidosis varies across ancestry groups, countries and health systems, but comparisons are distorted by access to CT, bronchoscopy, pathology and case definitions. A tertiary respiratory clinic will see a different spectrum from a district hospital. Asymptomatic thoracic disease can remain undetected; conversely, intensive evaluation of incidental lymphadenopathy detects cases that a symptom-based service misses. There is no defensible single India-wide incidence or prevalence that can be applied to one person or one state from older hospital series.
In India, the diagnostic burden is shaped by the much higher clinical salience of tuberculosis and by uneven availability of endobronchial ultrasound, culture, molecular tests, pathology expertise and longitudinal lung-function testing. Misclassification can occur in either direction: tuberculosis may be treated as sarcoidosis after a weak biopsy interpretation, or sarcoidosis may receive repeated empiric TB treatment without revisiting the diagnosis. Incidence statistics do not solve that problem. A local service should audit time to tissue diagnosis, microbiological sampling in granulomatous presentations, eye and cardiac screening completion, treatment toxicity and loss to follow-up. Those process measures are more actionable than copying a prevalence figure from another population.
Risk Factors
The cause of sarcoidosis remains incompletely defined. Genetic susceptibility, immune dysregulation and environmental or infectious exposures probably interact, but no routine blood test, genetic panel or exposure history proves the disease. Sarcoidosis is not contagious. Family history may raise awareness but should not lead to screening asymptomatic relatives with imaging. Sex, age and ancestry influence observed patterns, yet they cannot replace organ-specific assessment.
A key practical risk is diagnostic error. Previous tuberculosis, contact history, weight loss, fever, night sweats, immunosuppression, HIV risk, diabetes, silica exposure and travel modify the likelihood and consequences of infection. Drugs including interferons, immune checkpoint inhibitors and some antiretroviral therapies can trigger sarcoid-like reactions. Occupational beryllium or other mineral exposure needs a careful lifetime job history because chronic beryllium disease can closely resemble sarcoidosis. Risks of organ damage include reduced lung function, pulmonary hypertension, uveitis, ventricular arrhythmia, conduction block, renal dysfunction from disordered calcium metabolism, and neurological deficits. Starting glucocorticoids without a diagnostic plan can suppress symptoms while allowing untreated infection to progress.
Diagnosis
The diagnostic question is not simply whether a scan resembles sarcoidosis; it is whether the clinical syndrome and tissue pattern fit after important alternatives have been tested proportionately.
History
Ask about dry cough, breathlessness, chest pain, wheeze, fatigue, fever, weight change, palpitations, syncope, presyncope, eye pain, redness, photophobia, visual change, skin lesions, facial weakness, headache, neuropathic symptoms, renal stones and joint symptoms. Establish tuberculosis exposure, previous treatment, contact, constitutional symptoms, HIV risk where relevant, fungal or travel exposure, medicines, immune status, occupation and dust or metal work. Record duration, trajectory, fertility or pregnancy plans, alcohol use and previous corticosteroid or immunosuppressant exposure.
Examination
Measure oxygen saturation at rest and exertion when appropriate, respiratory rate, pulse, blood pressure and weight. Examine for crackles, wheeze, lymph nodes, hepatosplenomegaly, erythema nodosum, lupus pernio-like lesions, scars or tattoo inflammation, parotid enlargement, joint swelling and neurological deficit. Ask about vision even if the eye looks quiet; symptomatic ocular disease needs urgent ophthalmic assessment. Document pulse irregularity, bradycardia, syncope history and signs of heart failure because cardiac sarcoidosis can be clinically silent until dangerous.
Investigations
Initial evaluation usually includes chest radiography, lung function including diffusion capacity when available, ECG, basic blood count, renal and liver function, serum calcium and an ophthalmic assessment. CT characterises thoracic disease but does not prove it. Select microbiological samples for TB and other infection according to phenotype and local pathway; sputum, induced sputum, bronchoalveolar lavage, tissue culture, nucleic-acid testing and HIV testing may each be appropriate. Endobronchial ultrasound-guided node sampling is often useful where accessible. Histology should be reviewed with clinical and microbiological context. ATS guidance recommends baseline eye examination, serum creatinine, alkaline phosphatase and calcium testing in relevant patients, and ECG for extracardiac sarcoidosis without cardiac symptoms; advanced cardiac testing is guided by symptoms or abnormalities.
Differential Diagnosis
Tuberculosis is a first-order differential diagnosis in India, especially with fever, weight loss, cavitation, necrotic nodes, exposure, immunosuppression or a compatible microbiological result. Non-necrotising granulomas do not exclude TB, and a negative single test does not invariably exclude it when pre-test probability is high. Fungal infection, atypical mycobacteria, leprosy in selected phenotypes, HIV-associated conditions and parasitic or regional infections require context-specific consideration.
Other mimics include lymphoma, metastatic cancer, pneumoconiosis, chronic beryllium disease, hypersensitivity pneumonitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, common variable immunodeficiency-associated granulomatous disease and drug-induced sarcoid-like reactions. Bilateral hilar adenopathy can occur with lymphoma and infection; erythema nodosum is not specific; and elevated serum ACE is neither diagnostic nor sufficiently reliable to rule disease in or out. In a deteriorating patient, do not keep relabelling treatment failure as refractory sarcoidosis until infection, embolism, cardiac disease, drug toxicity and an alternative diagnosis have been reassessed in a multidisciplinary forum.
Management
Management starts with organ-risk stratification and shared decision-making, not a reflex prescription. Observe selected people with mild, stable disease and reliable follow-up, documenting symptoms, imaging and function. Treat when disease threatens organ function, is progressive, or causes major quality-of-life impairment after alternatives have been addressed. Pulmonary decisions should incorporate symptoms, spirometry, diffusion capacity, imaging trend, oxygen requirement, pulmonary hypertension assessment and competing diagnoses rather than an isolated CT stage.
Glucocorticoids are generally first-line systemic treatment when treatment is indicated, but their dose, route, duration and taper require organ-specific specialist planning. ERS recommendations cover pulmonary, cutaneous, cardiac, neurological disease and fatigue, with glucocorticoid-sparing options considered when disease persists or toxicity is unacceptable. Before immunosuppression, complete a documented infection evaluation, TB assessment under current national and institutional policy, vaccination review, pregnancy counselling and baseline safety tests. Exercise rehabilitation, smoking cessation, symptom management, work advice and mental-health support can be important even where immunosuppression is not chosen. Arrange serial monitoring that can detect progression and treatment harm early; do not judge response solely by ACE level or symptom fluctuation.
Prescribing Information
Systemic corticosteroids can cause hyperglycaemia, hypertension, fluid retention, mood change, insomnia, cataract, glaucoma, osteoporosis, myopathy and infection. Assess diabetes, blood pressure, bone health, eye risk, infection risk and concomitant medicines before and during treatment. A person who develops fever, productive cough, haemoptysis, new breathlessness or significant exposure to TB while immunosuppressed needs clinical review rather than an automatic steroid increase. Steroids must not be stopped suddenly after prolonged therapy without a supervised taper and adrenal-risk plan.
Methotrexate, azathioprine, mycophenolate or biologic therapy may be used by specialists as steroid-sparing or escalation therapy, but they are not interchangeable. Each has distinct pregnancy, liver, marrow, renal, pulmonary, infection, drug-interaction and monitoring requirements. Methotrexate for inflammatory disease is normally weekly, not daily; a written weekly schedule and folate plan help prevent catastrophic errors. Anti-TNF therapy can reactivate or worsen infections and needs specialist infection screening. Drug choices must follow Indian regulatory status, local formulary, laboratory capacity and expert oversight. This guide intentionally gives no regimen: medicine selection in sarcoidosis depends on the organ involved and the certainty that infection has been excluded.
When to Refer
Refer to respiratory medicine or an appropriate multidisciplinary service for suspected sarcoidosis with abnormal imaging, persistent respiratory symptoms, extrapulmonary features, uncertain granulomatous pathology or any contemplated systemic immunosuppression. Early ophthalmology review is needed for eye symptoms, abnormal screening or suspected uveitis; vision loss can be preventable if assessed promptly. Refer urgently to cardiology for palpitations, syncope, presyncope, abnormal ECG, conduction disease, ventricular arrhythmia, reduced ventricular function or suspected cardiac sarcoidosis.
Neurological symptoms such as facial weakness, focal deficit, seizures, meningitic headache, visual pathway symptoms or peripheral neuropathy require urgent neurology input and infection-aware imaging strategy. Nephrology may be needed for renal impairment, stones, hypercalcaemia or difficult electrolyte disturbance. Dermatology can help when an accessible lesion offers a lower-risk diagnostic biopsy. A referral should include chronology, imaging, lung function, pathology wording, microbiology and TB tests with dates, immune status, medicines, exposure history and all previous anti-TB or immunosuppressive treatment. Do not delay referral while waiting for a non-essential biomarker.
Red Flags
Same-day assessment is needed for syncope, sustained palpitations, bradycardia, chest pain with instability, new heart failure, severe hypoxaemia, rapidly worsening breathlessness, haemoptysis, confusion, severe hypercalcaemic symptoms or acute renal deterioration. These may represent cardiac sarcoidosis, arrhythmia, pulmonary embolism, infection, advanced pulmonary disease, drug toxicity or another emergency rather than uncomplicated sarcoidosis.
Painful red eye, photophobia, sudden visual loss or new floaters requires urgent ophthalmic assessment. Facial weakness, seizure, focal weakness, altered consciousness, severe headache or bladder disturbance needs urgent neurological evaluation and must not be assumed to be neurosarcoidosis. Fever, rigors, weight loss, night sweats, productive cough or new infiltrates during corticosteroid or biologic treatment should trigger infection assessment, including TB where epidemiologically relevant. In a person receiving immunosuppression, muted inflammatory markers and absent high fever do not safely exclude serious infection.
Indian Clinical Context
Sarcoidosis and tuberculosis can be difficult to distinguish in Indian practice because both can present with constitutional symptoms, lymphadenopathy, pulmonary infiltrates and granulomatous histology. The clinical consequence of error is asymmetric: immunosuppression in unrecognised TB can be dangerous, while prolonged empiric TB treatment can delay treatment of another disorder and add toxicity. Use National TB Elimination Programme and institutional diagnostic pathways, obtain relevant microbiology before immunosuppression where feasible, and document why the evidence favours or does not favour TB. Neither a negative tuberculin-based test nor a non-necrotising granuloma independently settles the question.
Access to EBUS, PET imaging, cardiac MRI, FDG-PET, specialist pathology and repeated lung function testing varies widely. A safe plan names what is available locally and the referral centre for what is not. Written medicine instructions, glucose and blood-pressure monitoring, affordable laboratory follow-up, contraception and pregnancy planning, and transport for urgent eye or cardiac symptoms should be discussed without promising services or reimbursement. NMC competency outcomes support recognition, disciplined differential diagnosis and appropriate consultation; they do not authorise learners to initiate immunosuppression. International ATS and ERS guidance is evidence support, not a substitute for India-specific infection control or drug policy.
NMC Competency Mapping
Sarcoidosis is a useful integrated case for NMC CBME learning: construct a respiratory and constitutional history; elicit extrapulmonary symptoms; interpret a chest radiograph and basic lung function report; formulate a differential for granulomatous disease; and decide when tissue, microbiology, eye examination, ECG or specialist referral is required. The learner should explain why non-necrotising granulomas are supportive but not pathognomonic and why TB exclusion changes the safety of corticosteroids.
Relevant outcomes span General Medicine respiratory and systemic disease assessment, Microbiology and Community Medicine principles of tuberculosis evaluation, Pharmacology safe corticosteroid and immunosuppressant use, Radiology image interpretation, Pathology granulomatous inflammation, and professional communication about uncertainty. Learners should document a problem list and safety-netting plan, recognise cardiac and ocular alarms, and communicate why a diagnosis may remain provisional. They should not independently classify a granulomatous biopsy as sarcoidosis, decide that TB is excluded on one test, or start steroid-sparing therapy without appropriate specialist supervision. This mapping is educational rather than a claim of disease-specific NMC prescribing authority.
Key Exam Pearls for NEET PG
Sarcoidosis is classically associated with bilateral hilar lymphadenopathy and non-caseating granulomas, but neither finding alone is diagnostic. The exam-safe statement is that diagnosis requires compatible clinical features and exclusion of other granulomatous causes, particularly tuberculosis in India. Serum ACE can be elevated but lacks sufficient specificity and sensitivity for diagnosis or response monitoring. Hypercalcaemia or hypercalciuria can occur through granuloma-associated vitamin-D metabolism and may cause stones or renal impairment.
Löfgren syndrome classically combines bilateral hilar lymphadenopathy, erythema nodosum and acute polyarthritis or periarthritis, often around the ankles. Lupus pernio refers to chronic violaceous facial lesions and carries a different clinical implication from systemic lupus erythematosus. Heerfordt syndrome is a classic association of uveitis, parotid enlargement, fever and facial palsy. These patterns raise suspicion but do not cancel infection work-up when epidemiology or phenotype requires it.
Pulmonary function may show restriction and reduced diffusion capacity, but obstruction or normal testing can occur. Cardiac involvement may produce AV block, ventricular arrhythmia, heart failure, palpitations or syncope; a patient with these symptoms needs an urgent cardiac pathway. Ocular disease can threaten sight. Neurosarcoidosis has diverse presentations and is a diagnosis of careful exclusion. Treatment is driven by threatened organ function, progression and quality of life, not by a radiograph alone. Glucocorticoids are commonly first-line when treatment is needed; steroid-sparing drugs require adverse-effect and infection monitoring.
On chest radiography, classic Scadding stages describe thoracic appearances rather than an individual prognosis or a treatment mandate: stage I has hilar lymphadenopathy, stage II adds parenchymal infiltrates, stage III has infiltrates without hilar enlargement and stage IV describes fibrosis. They should not be confused with severity of extrapulmonary disease. Endobronchial ultrasound-guided nodal sampling can provide tissue in appropriate thoracic disease; transbronchial biopsy, skin lesion biopsy or other routes are selected according to access and risk. A negative biopsy may reflect sampling rather than prove absence of disease.
For Indian examination and bedside reasoning, pulmonary TB remains the pivotal alternative, especially when fever, weight loss, necrosis, cavitation or microbiological evidence is present. Erythema nodosum is also seen with TB, infection and other inflammatory disorders. Steroids can improve symptoms from several causes and therefore response to steroids does not retrospectively prove sarcoidosis. Always match the answer to the requested action: stabilise arrhythmia or visual emergency first, establish microbiology before immunosuppression when possible, and use multidisciplinary review when pathology and clinical findings conflict.
Frequently Asked Questions
Can a non-caseating granuloma on biopsy prove sarcoidosis?
No. Non-necrotising granulomas support sarcoidosis only in a compatible clinical context after alternatives have been considered. Tuberculosis, fungal infection, exposure-related disease, drugs, immune disorders and malignancy can produce overlapping pathology. The sampling site, stains, cultures or molecular tests, imaging pattern, immune status and local epidemiology all matter. A pathology report should be discussed with the clinician and microbiology team rather than treated as a standalone final diagnosis.
Why is tuberculosis testing important before steroids for suspected sarcoidosis?
Corticosteroids and other immunosuppressants can worsen or mask infection. In India, TB is a major alternative diagnosis in many granulomatous presentations, and the necessary tests depend on symptoms, imaging, specimen access and local pathways. A single negative test may not exclude TB when clinical probability remains high. The safest approach is a documented infection assessment and specialist discussion before immunosuppression, with urgent review if constitutional or respiratory symptoms develop during treatment.
Does every person with sarcoidosis need systemic treatment?
No. Some people with mild, stable disease can be observed with planned review, while others need treatment because an organ is threatened, disease progresses or symptoms substantially impair life. The decision is individual and depends on lungs, eyes, heart, nervous system, kidneys, skin, function, imaging, physiology and reliable follow-up. Starting treatment simply because a scan is abnormal can expose a patient to avoidable toxicity; delaying treatment in eye, heart or neurological disease can also be harmful.
What symptoms should prompt urgent assessment in known sarcoidosis?
Urgent assessment is appropriate for syncope, new sustained palpitations, severe chest symptoms, rapid breathlessness, low oxygen readings, haemoptysis, sudden visual change, painful red eye, seizure, focal neurological deficit, confusion or severe illness during immunosuppression. These symptoms may be caused by sarcoidosis but can also reflect infection, embolism, arrhythmia, medication toxicity or another emergency. Bring the current medicine list, imaging and pathology reports when possible, but do not delay emergency care to collect records. New fever, weight loss, night sweats or productive cough during treatment also needs prompt infection review, particularly where TB remains plausible. If emergency transport is difficult, contact the nearest emergency service immediately and avoid driving after syncope or severe visual disturbance. A companion should remain with an acutely unwell person until assessed.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic